357 related articles for article (PubMed ID: 24827408)
1. Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.
Schuster DJ; Metcalf MD; Kitto KF; Messing RO; Fairbanks CA; Wilcox GL
Br J Pharmacol; 2015 Jan; 172(2):642-53. PubMed ID: 24827408
[TBL] [Abstract][Full Text] [Related]
2. Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking.
Ong EW; Xue L; Olmstead MC; Cahill CM
Br J Pharmacol; 2015 Jan; 172(2):615-29. PubMed ID: 24819092
[TBL] [Abstract][Full Text] [Related]
3. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
4. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy.
Stone LS; MacMillan LB; Kitto KF; Limbird LE; Wilcox GL
J Neurosci; 1997 Sep; 17(18):7157-65. PubMed ID: 9278550
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of δ- and μ-opioid receptor agonists promotes peripheral opioid receptor function.
Schramm CL; Honda CN
Pain; 2010 Dec; 151(3):763-770. PubMed ID: 20970925
[TBL] [Abstract][Full Text] [Related]
6. The delta-opioid receptor is sufficient, but not necessary, for spinal opioid-adrenergic analgesic synergy.
Chabot-Doré AJ; Millecamps M; Stone LS
J Pharmacol Exp Ther; 2013 Dec; 347(3):773-80. PubMed ID: 24039246
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase Cε is required for spinal analgesic synergy between delta opioid and alpha-2A adrenergic receptor agonist pairs.
Schuster DJ; Kitto KF; Overland AC; Messing RO; Stone LS; Fairbanks CA; Wilcox GL
J Neurosci; 2013 Aug; 33(33):13538-46. PubMed ID: 23946412
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
Dietis N; Niwa H; Tose R; McDonald J; Ruggieri V; Filaferro M; Vitale G; Micheli L; Ghelardini C; Salvadori S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Pharmacol; 2018 Jul; 175(14):2881-2896. PubMed ID: 29524334
[TBL] [Abstract][Full Text] [Related]
9. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
[TBL] [Abstract][Full Text] [Related]
10. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
[TBL] [Abstract][Full Text] [Related]
11. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
12. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
[TBL] [Abstract][Full Text] [Related]
13. Change in functional selectivity of morphine with the development of antinociceptive tolerance.
Macey TA; Bobeck EN; Suchland KL; Morgan MM; Ingram SL
Br J Pharmacol; 2015 Jan; 172(2):549-61. PubMed ID: 24666417
[TBL] [Abstract][Full Text] [Related]
14. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
15. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
[TBL] [Abstract][Full Text] [Related]
16. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
18. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
19. Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.
Kabli N; Martin N; Fan T; Nguyen T; Hasbi A; Balboni G; O'Dowd BF; George SR
Br J Pharmacol; 2010 Nov; 161(5):1122-36. PubMed ID: 20977461
[TBL] [Abstract][Full Text] [Related]
20. Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice.
Bruce DJ; Peterson CD; Kitto KF; Akgün E; Lazzaroni S; Portoghese PS; Fairbanks CA; Wilcox GL
Anesthesiology; 2019 Sep; 131(3):649-663. PubMed ID: 31343460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
